MedTrace Logo

Effect of Remimazolam on Postoperative Nausea and Vomiting

NCT05439057 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2025-06-18

No results posted yet for this study

Summary

The present trial is to study the effect of low dose remimazolam on postoperative nausea and vomiting (PONV) in patients at risks of PONV (women, postoperative use of opioid, nonsmokers) undergoing laparoscopic cholecystectomy.

Conditions

  • Postoperative Nausea and Vomiting

Interventions

DRUG

Remimazolam

Remimazolam is infused at a rate of 0.3 mg/kg/hr from induction of anesthesia until 20 minutes before the end of operation.

DRUG

Control

Normal saline is infused at a rate of 0.3 ml/kg/hr from induction of anesthesia until 20 minutes before the end of operation.

Sponsors & Collaborators

  • Inje University

    lead OTHER

Principal Investigators

  • In-Jung Jun, MD.PhD. · Associate professor

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-13
Primary Completion
2024-10-31
Completion
2024-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05439057 on ClinicalTrials.gov